Dare Bioscience, Inc. Cost of Revenue
Dare Bioscience, Inc. (DARE) reported Cost of Revenue of $319.89 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-13
- Dare Bioscience, Inc. cost of revenue for the quarter ending 2026-06-30 was $319.89K.
- Dare Bioscience, Inc. cost of revenue for the quarter ending 2026-03-31 was $242.32K.
- Dare Bioscience, Inc. cost of revenue for the quarter ending 2025-06-30 was $0.00.
- Dare Bioscience, Inc. cost of revenue for the quarter ending 2025-03-31 was $0.00.
- Dare Bioscience, Inc. cost of revenue for fiscal 2025 was $295.80K.
- Dare Bioscience, Inc. cost of revenue for fiscal 2024 was $0.00.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 12 month |
|---|---|---|---|
| 2026-06-30 | $319.89K 10-Q · filed 2026-08-13 | $562.21K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $242.32K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $295.80K 10-K · filed 2026-03-26 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |